All posts by admin

Business Wire India

 

• Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to – or even replacing – gadolinium-based MRI agents
• A manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designation
• The program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs

 

GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use in adults and pediatric patients aged 2 years and older with MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. FDA Fast Track designation expedites the review of new therapeutics and medical imaging agents that have the potential to address significant unmet patient needs.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423262096/en/

 

 

 

MRI contrast agents enhance the visualization of abnormal structures or lesions during imaging procedures and help clinicians better distinguish between healthy and diseased tissue. Mangaciclanol is intended for general-purpose MR imaging and demonstrates comparable relaxivity (the ability to enhance signal intensity) to market-leading gadolinium-based agent, gadobutrol, with early clinical images suggesting similar diagnostic capability. Unlike gadolinium, which is a rare-earth metal, manganese is present in our food, and is an endogenous element, naturally occurring and autoregulated in the body. The macrocyclic ‘cage-like’ structure of mangaciclanol lessens the possibility of retention.

 

Approximately one-third of global MRI procedures require a contrast agent for effective diagnosis,¹ with around 65 million gadolinium contrast enhanced procedures globally each year.² As a rare-earth element, gadolinium supply is largely dependent on mining and processing infrastructure in China. Manganese, however, is abundantly available from multiple countries, including South Africa, Australia and Gabon, reducing the risk of supply challenges impacting patient care. Furthermore, as manganese is naturally found in water sources, mangaciclanol could also reduce environmental concerns associated with post-patient excreted contrast media in groundwater.

 

 

Dr Jit Saini, Chief Medical Officer, Pharmacutical Diagnostics, GE HealthCare, said, “Existing gadolinium-based contrast agents carry safety language associated with gadolinium retention. In comparison, mangaciclanol could offer an alternative for broad patient groups, including vulnerable patients and those requiring multiple scans, while still offering similar diagnostic performance. The FDA Fast Track designation recognizes the potential significance of mangaciclanol and aligns with our focus on advancing its development for patients.”

 

 

“As demand for diagnostic imaging continues to rise, we continue to advance our imaging agent pipeline to better meet the needs of patients,” said Peter Arduini, President and CEO, GE HealthCare. “This clinical milestone builds on GE HealthCare’s leadership in contrast media, as mangaciclanol has the potential to transform the MR imaging market and strengthen the resiliency of its supply chain.”

 

 

Phase 1 results for mangaciclanol showed the investigational agent was well tolerated in a first in human trial with no serious adverse events, no dose limiting toxicities, nor clinically relevant findings reported.

 

 

GE HealthCare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support 140 million patient procedures per year globally, equivalent to four procedures every second. For more than 40 years, GE HealthCare contrast media has been routinely used across MRI, X-ray/CT and ultrasound to enhance clinical images and support diagnosis.

 

 

Mangaciclanol is in clinical development and currently not approved for use.

 

 

About GE HealthCare Technologies Inc.

 

 

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

 

 

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

 

 

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.

 

 

¹ Contrast Agents of Magnetic Resonance Imaging and Future Perspective.Nanomaterials. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10343825/[europepmc.org]
²Recent Developments and Future Perspectives in Magnetic Resonance Imaging and Computed Tomography Contrast Media.Frontiers in Radiology. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12871431/

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260423262096/en/

 

Business Wire India

NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments.

 

This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time.

 

 

AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them.

 

 

AI is Becoming the Operating Layer of Global Commerce

 

 

NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what products are really available, and how markets operate.

 

 

Across the industry, however, the data and measurement required to support this shift remains incomplete. Product data is inconsistent, real-world purchasing behavior is fragmented, availability signals are unreliable, and measurement lacks objectivity. These gaps limit the accuracy, trust, and scalability of AI-driven commerce—and can determine whether products are represented, recommended, or overlooked entirely.

 

 

Building the Intelligence Layer for Agentic Commerce

 

 

The NIQ Commerce Lab will advance a core pillar of NIQ’s AI strategy: Commerce Intelligence.

 

 

Commerce Intelligence is NIQ’s approach to bringing together the full range of signals that shape the market—product, consumer, and retailer data—into a unified system that can understand complex dynamics and power AI-driven decisions that were previously out of reach.

 

 

“NIQ has built the data infrastructure for how commerce actually works,” said Jim Peck, Chairman and CEO of NIQ. “Enabled by AI, we are making a fundamental shift—from measurement and analytics to reading signals in real time and acting on them with confidence. Commerce Intelligence is how we will deliver the intelligence layer the market will depend on, today and in the future.”

 

 

Through the Commerce Lab, NIQ will address six interconnected opportunities required to make Commerce Intelligence real at scale, including:

 

 

• Preference Intelligence — understanding what consumers want
• Product Intelligence — ensuring products are accurately represented
• Availability Intelligence — connecting recommendations to real-world inventory
• Purchase Verification — validating what was actually bought
• Channel Measurement — establishing objective performance and ROI
• Optimization Intelligence — enabling continuous improvement

 

Together, these capabilities are designed to form the intelligence layer that allows AI systems to move from approximation to precision.

 

Why NIQ

 

 

NIQ is uniquely advantaged to build Commerce Intelligence at global scale, combining the data infrastructure, retailer relationships, and neutrality required to fuel AI-driven decisions in commerce.

 

 

• Proprietary Data Infrastructure: NIQ operates data pipelines that ingest point-of-sale transactions from thousands of retailers across nearly every country where commerce happens. This is a technology asset that cannot be recreated by any platform, retailer, or new entrant within the relevant time horizon.
• Structured Product Knowledge at Scale: NIQ’s product catalog represents hundreds of millions of items enriched with billions of structured attributes, generated and maintained by thousands of AI models running continuously. This is the system AI agents need to resolve consumer intent to specific products.
• Closed-Loop Measurement: NIQ links behavior across platforms, channels, and retailers to verified purchase outcomes. This is the measurement infrastructure the category requires to function, and no platform with commercial interests in the transaction can credibly provide it.
• Neutral Advantaged Technology Partner: As an independent party with no retail operation, no advertising platform, and no channel conflict, NIQ is the go-to infrastructure provider participants can trust with the data the market requires.

 

Enabling the Next Phase of Commerce

 

The Commerce Lab will serve to develop the intelligence infrastructure to:

 

 

• Identify emerging commerce signals and dynamics shaping how decisions are made
• Develop new data and measurement capabilities
• Run pilot programs to understand agentic purchasing behavior
• Partner across the AI and commerce ecosystem
• Establish emerging industry standards

 

Leadership

 

NIQ is accelerating its AI agenda with the appointment of Lisa Lovallo Ceppos as Head of AI Commerce. Joining from Google, where she led product strategy for ad effectiveness measurement and Google Maps integration into Vertex AI, Lovallo Ceppos will lead NIQ’s AI commerce product strategy and the continued development of the Commerce Lab—further cementing NIQ’s position at the forefront of Commerce Intelligence.

 

 

To learn more about NIQ’s new Commerce Lab, visit niq.com/agentic-commerce.

 

 

About NIQ

 

 

NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.

 

 

With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.

 

 

For more information, please visit www.niq.com.

 

 

Forward-Looking Statements

 

 

This press release contains forward-looking statements. These forward-looking statements address various matters including statements about anticipated timelines, benefits, features, and outcomes of NIQ Commerce Lab and related capabilities and other statements contained in this press release that are not historical facts. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Forward-looking statements speak only as of the date made and NIQ undertakes no obligation to update them except as required by law.

 

 

#NIQ-General

 

 

All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

 

 

© 2026 Nielsen Consumer LLC. All Rights Reserved.

 

 

FAQ: NIQ Commerce Lab and AI-Driven Commerce

 

 

1. What is the NIQ Commerce Lab?

 

 

The NIQ Commerce Lab is where NIQ discovers, builds, and launches the intelligence infrastructure for AI-driven commerce. It showcases new data assets, measurement methodologies, and partnerships that help the industry better understand and improve how products are discovered, selected, and purchased in AI-powered environments.

 

 

2. What is Commerce Intelligence?

 

 

Commerce Intelligence is NIQ’s new approach to bringing together the full range of signals that shape the market—product, consumer, and retailer data—into a unified system that can understand complex dynamics and power AI-driven decisions that were previously out of reach.

 

 

This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how products are discovered, evaluated, and purchased.

 

 

3. Why is AI-driven commerce different from traditional e-commerce?

 

 

In AI-driven or agentic commerce, AI systems and agents increasingly influence or execute product discovery, selection, and purchasing decisions. This creates new signals as consumers change how they interact with brands and platforms, shifting from search and browsing to automated, intent-driven recommendations and transactions.

 

 

4. What problems is NIQ solving through the Commerce Lab?

 

 

NIQ is advancing a set of interconnected intelligence opportunities that power this shift:

 

 

1. Preference Intelligence — understanding who consumers are and what they want
2. Product Intelligence — ensuring products are accurately represented and discoverable
3. Availability Intelligence — connecting recommendations to real-world inventory and fulfillment
4. Purchase Verification — validating what was actually bought across channels
5. Channel Measurement — establishing objective performance and ROI standards
6. Optimization Intelligence — enabling continuous improvement across the commerce lifecycle

 

Together, these six intelligence opportunities define the data and measurement foundation required for AI-driven commerce to operate reliably and at scale.

 

5. Why does AI-driven commerce require new measurement standards?

 

 

As AI systems begin to influence and execute transactions, traditional digital metrics alone are no longer sufficient. Business decision-makers need objective, third-party measurement to understand performance, validate ROI, and compare results across platforms and channels before shifting meaningful budgets and attention to a new channel. Without this, adoption of AI-driven commerce will be limited.

 

 

6. How does NIQ enable AI-driven commerce?

 

 

NIQ enables AI-driven commerce by providing:

 

 

• Real-world transaction data
• Deep consumer intelligence linked to demographics and behavior
• Rich product data and attributes for accurate matching to user intent
• Independent, third-party measurement and ROI validation

 

These capabilities help ensure AI systems operate with accurate, complete, and trusted information.

 

7. What makes NIQ different from other data or AI providers?

 

 

NIQ is uniquely advantaged to build Commerce Intelligence at global scale, combining the data infrastructure, retailer relationships, and neutrality required to fuel AI-driven decisions in commerce.

 

 

8. What is agentic commerce?

 

 

Agentic commerce refers to AI-driven systems or agents that can discover products, evaluate options, and make or influence purchasing decisions on behalf of consumers or businesses. This represents a shift from manual search and browsing to automated, intent-driven commerce experiences.

 

 

While the industry often refers to this shift as agentic commerce, it is only one way AI may show up. As AI transforms platforms, interfaces, and workflows, NIQ expects that its usage in commerce will go beyond standalone “agents.”

 

 

The more fundamental change is that AI is becoming the system that drives decisions across commerce—regardless of how it is delivered.

 

 

That is why NIQ focuses on Commerce Intelligence: the data, measurement, and context that power these decisions. Whether through agents, assistants, or embedded AI systems, outcomes depend on the quality of the intelligence behind them.

 

 

9. How will AI-driven commerce impact businesses?

 

 

AI-driven commerce is changing the consumer path to purchase in new ways that we don’t fully understand yet. What we do know is that it will change how companies:

 

 

• Reach and influence consumers
• Optimize product discovery and assortment
• Measure performance and ROI
• Allocate marketing and media spend

 

Businesses that adapt to AI-driven decision environments will be better positioned to compete and grow.

 

10. What is NIQ’s role in the future of commerce?

 

 

NIQ is building the Commerce Intelligence layer that powers AI-driven commerce. Through the Commerce Lab and its global data assets, NIQ is helping define how commerce will be measured, optimized, and scaled in an AI-driven world.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260428009576/en/

 

Business Wire India

India’s residential landscape is evolving, and so is the demand for reliable, well-designed, and functional home interiors. However, this group also faces various hurdles. For many homeowners, the process of transforming an empty apartment into a dream home remains complex and uncertain. Challenges such as a lack of pricing transparency, unreliable vendors, inconsistent material quality, and difficulty visualising the outcome often make the interior design journey overwhelming.

In response to these industry-wide concerns, NoBroker, a proptech company, launched NoBroker Interiors Services in 2018 to deliver hassle-free interior services with the highest-quality materials at the best prices. In the last 8 years, NoBroker Interiors has opened a total of 5 experience centres in Bangalore, Hyderabad and Pune. These experience centres serve as interactive spaces where customers can explore and plan their homes with confidence.

For the first time ever, homeowners can access a physical, immersive space designed to simplify the home design journey. These NoBroker Interior centres are designed to bridge the gap between conceptual understanding, practical practices, and real-world execution. Unlike traditional interior consultations that rely heavily on digital renders, catalogues, and past work from other homes, NoBroker Interiors Experience Centres offer a more tangible and interactive environment. Homeowners can walk through life-sized layouts of modular kitchens, wardrobes, bedrooms, and living spaces and explore a wide range of materials, finishes such as laminates, membranes, paints, and hardware. This hands-on approach enables customers to assess quality, understand functionality, and make informed decisions with clarity and confidence. More importantly, by interacting with real-time layouts and design elements, homeowners can create, refine, and expand their vision while receiving expert guidance from experienced designers.

Beyond serving as showrooms, the NoBroker Interiors Experience Centres act as consultation hubs where customers can engage directly with professionals to discuss design preferences and project requirements. By combining technology-driven processes with personalised expertise, NoBroker Interiors guarantees its commitment to transparency, efficiency, and customer satisfaction.

In its vision for the future, NoBroker Interiors Experience Centres aims to redefine the interiors industry. As part of its growth strategy, the brand aims to expand its Experience Centres and services to two more Experience Centres in the April to June quarter of 2026 and open five more before the end of the year. This initiative will make professional, accessible interior solutions available to a broader audience. With access to some of the industry’s most experienced designers and a focus on delivering quality-driven outcomes, NoBroker Interior is on the path to redefining how Indians design their homes by providing reliability, expertise, and a seamless interior journey.

As urban housing continues to grow and evolve, initiatives like NoBroker Interiors Experience Centres indicate a shift towards more accessible, transparent, and customer-centric interior design solutions in India. For Bangalore homeowners, particularly those navigating interiors for the first time, these experience centres serve as a valuable starting point.

To know more about the NoBroker Interior Experience Centre, visit them at:

Bangalore:

1. NoBroker Experience Centre HSR: Address: 448, 17th Cross Rd, Sector 4, HSR Layout, Bengaluru, Karnataka 560102
2. NoBroker Experience Centre Horamavu: Address: No 41, HSR Grandeur Horamavu Main Road Chikkahanumantha, Narayana Reddy Layout Rd, Signal, Horamavu, Bengaluru, Karnataka 560113
3. NoBroker Experience Centre Whitefield: 4th floor, Garden of Eden, Survey No 4, Khata 799, Whitefield Main Road, Pattandur Agrahara Village, next to Royal Mart, KR Puram, Whitefield, Bengaluru, Karnataka 560066

Pune:

1. NoBroker Experience Centre Wakad: 305, Bhumkar Nagar, Wakad, Pimpri-Chinchwad, Maharashtra 411057
2. NoBroker Experience Centre Kharadi (Opening in June’26)

Hyderabad:

1. NoBroker Experience Centre Gachhibowli: Kondapur Main Road, opposite Le Meridien, Banjara Basthi, Jayabheri Enclave, Gachibowli, Hyderabad, Telangana 500084

Contact Details for booking enquiry: Phone: +91-804544 2747

Business Wire India

Kioxia Corporation today announced the KIOXIA BG8 Series solid state drives (SSDs), the next evolution of its client SSD lineup designed for PC OEM customers. Delivering PCIe^® 5.0 speed to the mainstream segment, the KIOXIA BG8 Series combines next-generation capability with efficient operation and broad design flexibility for slim laptops, commercial and consumer notebooks, and desktop systems.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422036742/en/

 

 

 

Built with Kioxia’s BiCS FLASH™ generation 8 TLC-based 3D flash memory, the KIOXIA BG8 Series advances both performance and power efficiency. Compared to the previous generation⁽¹⁾, the KIOXIA BG8 Series achieves up to 47 % higher sequential read, 67 % higher sequential write, 44 % higher random read, and 30 % higher random write performance.

 

With sequential read speed of up to 10,300 MB/s and sequential write speed of up to 10,000 MB/s, along with random read and write performance reaching up to 1.4 million and 1.3 million IOPS respectively, the KIOXIA BG8 Series enables responsive system performance across a wide range of client workloads.

 

 

The DRAM-less KIOXIA BG8 Series supports a Host Memory Buffer (HMB) feature, leveraging host system memory to help balance performance, power consumption, and cost. Designed with flexibility in mind, the KIOXIA BG8 Series is available in multiple M.2 form factors – Type 2230, Type 2242, and Type 2280 – supporting a broad range of system designs and mounting requirements.

 

 

Additional features include:

 

 

• PCIe^® 5.0 (Gen5 x4) and NVMe™ 2.0d compliant
• Self-Encrypting Drive (SED) support based on TCG Opal version 2.02
• Capacities of 512 GB, 1024 GB, and 2048 GB
• Optimized for slim and mainstream client PCs

 

The KIOXIA BG8 Series is currently sampling to select PC OEM customers, with PC shipments equipped with the SSD expected to begin from the second quarter of 2026 onwards.

 

Notes:
(1) Compared to KIOXIA BG7 Series SSDs

 

 

– Definition of SSD capacity: Kioxia Corporation defines a kilobyte (KB) as 1,000 bytes, a megabyte (MB) as 1,000,000 bytes, a gigabyte (GB) as 1,000,000,000 bytes, a terabyte (TB) as 1,000,000,000,000 bytes, and a kibibyte (KiB) is 1,024 bytes. A computer operating system, however, reports storage capacity using powers of 2 for the definition of 1GB = 2^30 bytes = 1,073,741,824 bytes and 1TB = 2^40 bytes = 1,099,511,627,776 bytes and therefore shows less storage capacity. Available storage capacity (including examples of various media files) will vary based on file size, formatting, settings, software and operating system, and/or pre-installed software applications, or media content. Actual formatted capacity may vary.

 

 

– Read and write speed may vary depending on the host device, read and write conditions, and file size.

 

 

– IOPS: Input Output Per Second (or the number of I/O operations per second)- Availability of the SED model lineup may vary by region- NVMe is a registered or unregistered mark of NVM Express, Inc. in the United States and other countries.

 

 

– PCIe is a registered trademark of PCI-SIG.

 

 

– Other company names, product names and service names may be trademarks of third-party companies.

 

 

About Kioxia
Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with “memory” by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia’s innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems.

 

 

*Information in this document, including product prices and specifications, content of services and contact information, is correct on the date of the announcement but is subject to change without prior notice.

 

 

Customer Inquiries:
Global Sales Offices
https://www.kioxia.com/en-jp/business/buy/global-sales.html

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260422036742/en/

 

Business Wire India

• Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion

 

Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026.

 

“Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio,” said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10^th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.”

 

 

First Quarter 2026 Results

 

 

On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KRW 454.9 billion with an operating profit of KRW 144.0 billion. Revenue and operating profit in the fourth quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively.

 

 

First quarter growth surpassed the January 2025 guidance by more than 10%, reflecting stronger-than-expected performance across the business.

 

 

Samsung Epis Holdings posted a consolidated revenue of KRW 453.9 billion and operating profit of KRW 90.5 billion. Non-cash accounting adjustments, including amortization of purchase price allocation (PPA)-related development costs, are reflected in consolidated revenue and operating profit, following a consolidated revenue of KRW 251.7 billion and operating loss of KRW 63.6 billion in November and December 2025.

 

 

[Samsung Bioepis Earnings, KRW billion]
	Q1’24	Q1’25	Q1’26	YoY Change
Revenue	280.1	400.6	454.9	+54.3 (+14%)
Operating Profit	38.1	127.9	144.0	+16.1 (+13%)

 

Business Updates

 

• In October 2025, Samsung Bioepis entered into a private label partnership with CVS Caremark, the Pharmacy Benefit Manager (PBM) division of CVS Health, for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia¹.
• BENEPALI™ (etanercept), Samsung Bioepis’ first biosimilar in Europe, continues to maintain its leadership position in the market as it celebrates its 10^th anniversary in Europe.
• In March, Samsung Bioepis expanded its development and commercialization partnership with Sandoz, on up to five biosimilar candidates including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), in multiple markets.
• Also in March, a Phase 1 first-in-human clinical trial for Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate, SBE303, has begun. Following the announcement, the company also presented a poster presentation of its nonclinical data at the American Association for Cancer Research (AACR) 2026 on April 20^th which demonstrates its encouraging efficacy, safety, tolerability and a promising ability to work in combination with existing immuno-oncology therapies.
• Samsung Bioepis’s second novel ADC candidate, SBE313, is currently in nonclinical development in collaboration with Phrontline Biopharma.

 

 

Disclaimer

 

This document contains ‘forward-looking statements’ regarding future expectations, projections, plans, and anticipation. ‘Forward-looking statements’ are matters that pertain to the Company’s future business and financial performance, and are subject to uncertainties such as trends in domestic and international financial markets, including but not limited to fluctuations in exchange rates and/or interest rates.

 

 

‘Forward-looking statements,’ by their nature, addresses matters that may be uncertain; actual results may be materially different from those expressed in this document.

 

 

About Samsung Epis Holdings Co., Ltd.

 

 

As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value through proactive R&D and investment and optimize business strategies for its subsidiaries, Samsung Bioepis and Epis NexLab. Samsung Epis Holdings continues to embrace future challenges and drive innovation by identifying new growth drivers and strengthening global collaboration platforms, thereby laying a solid foundation for the continued growth of its subsidiaries. For more information about Samsung Epis Holdings, please visit: www.samsungepisholdings.com.

 

 

About Samsung Bioepis Co., Ltd.

 

 

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

 

 

About Epis NexLab Co., Ltd.

 

 

Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab is focused on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Epis NexLab, please visit: www.samsungepisholdings.com.

 

 

Reference
¹ Prolia is a registered trademark of Amgen Inc.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260422191520/en/

 

Business Wire India

NIIT’s RPS Consulting has been honored with the 2026 Google Cloud Training Partner of the Year award for the Asia Pacific Region. This exceptional achievement marks the fourth consecutive year that RPS Consulting has received this prestigious recognition. The company has been awarded for its achievements in the Google Cloud ecosystem, helping joint customers accelerate digital transformation, build scalable cloud solutions, and drive measurable business outcomes.

 

This award highlights RPS Consulting’s continued focus on delivering high-quality cloud training, consulting, and implementation services that empower organizations to fully leverage Google Cloud technologies. By enabling enterprises with future-ready skills and solutions, RPS has played a vital role in bridging capability gaps in the cloud landscape.

 

Commenting on the announcement, Vishnupriya Raghavan, Sr. Vice President & Business Head, NIIT Ltd., said, “Being recognized as the 2026 Google Cloud Partner of the Year for Asia Pacific for the fourth consecutive year is a proud milestone for us. It reflects the trust our clients and partners place in us, the strength of our team, and the depth of our expertise in cloud skilling and certification. In collaboration with Google Cloud, we continue to help organizations build future-ready talent and accelerate their cloud journeys with confidence. This recognition reflects our strong commitment to customer success, innovation, and continuous learning.”

 

“The Google Cloud Partner Awards honor the strategic innovation and measurable value our partners bring to customers,” said Kevin Ichhpurani, President, Global Partner Ecosystem and Channels, Google Cloud. “We are proud to name RPS Consulting a 2026 Google Cloud Partner Award winner, celebrating their role in driving customer success over the last year.”

 

In 2025, RPS Consulting strengthened its position as a trusted cloud enablement partner by expanding its Google Cloud training portfolio, enabling thousands of professionals, and supporting enterprises in their cloud adoption journeys. The company’s focus on capability building and scalable learning solutions has contributed significantly to customer success across industries.

Business Wire India

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026.

 

• Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy.
• Widespread net sales growth of 25.5% year-on-year at constant currency¹,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%).
• Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion.
• Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemolizumab in children with moderate-to-severe atopic dermatitis and new data strengthening the Injectable Aesthetics portfolio to address latest patient needs, with pioneering research on menopause-related skin changes.
• Strengthened financial profile and shareholder returns through share repurchases, a dividend payment, and a successful Eurobond placement of 500 million EUR in March to fully repay the Term Loan, following the earlier replacement of the Revolving Credit Facility.
• Completed the transition to a free-float dominated shareholder base, following the full divestment by the EQT-led consortium of investors, marking the largest fully monetized capital gain from a single private equity fund.
• Confirming 2026 full-year guidance, with net sales growth of 17-20% year-on-year at constant currency and a Core EBITDA margin of approximately 26% at constant currency, with increased confidence to navigate a volatile environment.

 

“Galderma’s strong first quarter results reflect our commitment to advancing dermatology and delivering innovative solutions for consumers and patients worldwide. This marks a strong start to another year of key launches, sustained execution and scientific momentum, as well as the continued strengthening of our financial profile – all reinforcing our category leadership. Our integrated dermatology strategy continues to drive growth and we are well-positioned to build on this success throughout 2026.”   FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICER GALDERMA

Commercial performance

 

Galderma expects 2026 to be another year of opportunities as it continues to execute on its proven, growth-driven integrated dermatology strategy. Growth for the year is expected to be broad-based across its existing portfolio, complemented by new launches and geographic expansion.

 

 

For the first quarter of the year, Galderma achieved net sales of 1,473 million USD, representing year-on-year net sales growth of 25.5% at constant currency. As anticipated, net sales growth was particularly high in the first quarter. This was driven by the strong ramp-up of Nemluvio against a low comparative base, combined with the strong commercial performance across the rest of the portfolio, with Dermatological Skincare in particular delivering ahead of expectations. Growth was widespread across geographies and product categories, outperforming the market in each product category. Growth was driven predominantly by volume, complemented by positive price and mix effects.

 

 

Injectable Aesthetics

 

 

Injectable Aesthetics net sales for the first quarter of 2026 were 648 million USD, with year-on-year growth of 13.1% at constant currency.

 

 

Neuromodulators delivered net sales of 364 million USD, up 12.5% year-on-year at constant currency. Performance was broad-based and particularly high in Europe and Asia Pacific, with the U.S. also benefitting from some favorable phasing. Galderma outpaced the market in Neuromodulators in both reporting geographies, with Dysport continuing to grow and Relfydess on a strong ramp-up trajectory. Galderma continues to progress on the execution of its portfolio strategy, while advancing Relfydess regulatory reviews in additional markets.

 

 

Fillers & Biostimulators achieved net sales of 284 million USD, up 14.0% year-on-year at constant currency. Fillers & Biostimulators outpaced the market in both reporting geographies, with particularly strong growth in the U.S., which benefitted from favorable phasing. Galderma continues to strengthen its broad Restylane portfolio, delivering growth in a soft market. Key recent highlights include the U.S. FDA approval of RestylaneContour™ for the correction of temple hollowing and the global ‘Wake Up To Restylane’ campaign, positioning Restylane as an everyday natural beauty ally. Sculptra maintains its double-digit growth momentum in both geographies. In addition to strengthening Sculptra’s position in regenerative aesthetics and expanding into body indications in Europe, Galderma launched its ‘We Are All Sculptra’ program, following nine new patients over two years to highlight its real-life regenerative impact.

 

 

Dermatological Skincare

 

 

Dermatological Skincare net sales for the first quarter were 441 million USD, with year-on-year growth of 17.0% at constant currency.

 

 

Both Dermatological Skincare flagship brands, Cetaphil and Alastin, maintained strong growth momentum, also benefitting from a lower comparable base for the period. Growth was positive in both geographies, with particularly strong performance of Cetaphil in fast-growing International markets and of Alastin in the U.S. Outperformance in the category continues to be driven by focused execution, innovation and portfolio synergies.

 

 

Commercial execution remained strong, with e-commerce continuing as the fastest growing channel, including outstanding growth from Cetaphil in China. Alastin also strengthened partnerships with leading aesthetics clinics in the U.S. through Alastin Signature Practices, a premium in-office experience designed to elevate regenerative, peri-procedural skincare.

 

 

Galderma continued to support its core portfolio with differentiated innovation. For Cetaphil, this included the introduction of AM/PM Antioxidant Serums, a breakthrough daily system clinically designed to defend skin by day and support accelerated repair by night for sensitive, stressed skin. For Alastin, it included the U.S. launch of Alastin Regenerating Skin Nectar with TriHex+™ technology, a new formulation with our proprietary Octapeptide‑45 which helps reinforce skin structure, restore skin barrier and support long-term skin longevity.

 

 

Therapeutic Dermatology

 

 

Therapeutic Dermatology net sales reached 385 million USD for the first quarter of 2026, up 71.3% year-on-year at constant currency.

 

 

Growth was driven by Nemluvio’s continued strong launch trajectories in both reporting geographies, complemented by anticipated moderate growth from the mature Therapeutic Dermatology portfolio in International markets during the period. This more than offset the decline of the mature portfolio in the U.S.

 

 

Nemluvio net sales for the quarter were 185 million USD. The vast majority of sales came from the U.S., with a greater contribution from atopic dermatitis than prurigo nodularis.

 

 

In the U.S., Nemluvio paid new patient starts (NBRx) from the beginning of February to mid-March 2026 was trending at about 39% market share in prurigo nodularis and about 8% in atopic dermatitis. The majority of patients starting treatment continue to be new to biologics. Galderma also continues to expand its healthcare professional engagement, supported by real world experience data to reinforce Nemluvio’s efficacy on skin clearance, complementing its position as the itch relief treatment of choice.

 

 

In International markets, which represent only a small portion of total Nemluvio sales, the launch trajectory remains even stronger. Meanwhile, Galderma is also advancing regulatory reviews in additional top markets.

 

 

Science-led innovation & medical education

 

 

Galderma reinforced its leadership in dermatology during the first quarter through impactful data presentations and industry-leading medical education at global congresses and company-led platforms.

 

 

At the 2026 American Academy of Dermatology (AAD) Annual Meeting, Galderma presented 22 abstracts spanning its full portfolio. Highlights included late-breaking data for nemolizumab showing clinically meaningful benefits in children aged 2 to 11 with moderate-to-severe atopic dermatitis. These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities. It also represents a significant opportunity to improve patient lives, with up to 25% of children affected by atopic dermatitis and the currently limited approved treatment options for children living with moderate-to severe atopic dermatitis.

 

 

At 2026 Winter Clinical™ Miami, interim results from the OLYMPIA long-term extension study showed Nemluvio maintained disease control in prurigo nodularis for up to three years, with clinically meaningful improvements in itch intensity, skin lesions, and quality of life – the longest extension study in prurigo nodularis reported to date.

 

 

Earlier, at the Aesthetic & Anti-Aging Medicine World Congress 2026 (AMWC) in Monaco, Galderma presented 9 posters across its aesthetics portfolio, highlighting the regenerative benefits of Sculptra, the long-lasting efficacy of Restylane and the advanced clinical performance of Relfydess. The scientific program addressed emerging patient needs and trends, including medication-driven weight loss patients and perimenopausal women.

 

 

Finally, at the International Master Course on Aging Science (IMCAS) 2026, Galderma extended its aesthetics leadership with findings from a global survey of over 4,300 women revealing a significant knowledge gap around menopause-related skin changes and underscored its commitment to including menopausal status in all injectable aesthetics clinical trials. Galderma also presented new data on Sculptra, Restylane and Relfydess, building on clinical updates from its neuromodulator portfolio highlighted earlier at the TOXINS 2026 International Conference.

 

 

Financial profile

 

 

Galderma demonstrated meaningful progress in further strengthening its financial profile in the first quarter of the year, as evidenced by its investment grade ratings from S&P (BBB, positive) and Fitch (BBB, positive).

 

 

Galderma replaced in February 2026 its Revolving Credit Facility originally implemented at the time of its 2024 IPO, with significantly improved terms and a size increase from 0.7 to 1 billion USD. In March, Galderma also successfully issued a Eurobond, for a total of 500 million EUR, with proceeds used for full early Term Loan repayment.

 

 

Galderma also continued to demonstrate its commitment to superior shareholder returns. This included share repurchases of 232 million CHF in the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) which took place in March. Funded from existing liquidity on hand, they are to be held in treasury to support Galderma’s employee participation plans, business development activities and/or treasury management. This final accelerated bookbuild offering marks the full divestment by the EQT-led consortium of investors. Emphasizing Galderma’s reliable performance and attractive outlook as a stand-alone company, it is the largest fully monetized capital gain from a single fund in the history of global private equity.

 

 

At the recent Annual General Meeting, following another record year, a dividend payment of 0.35 CHF (gross) per share was approved out of reserves from capital contributions.²

 

 

Outlook

 

 

Galderma is confirming its full-year guidance for 2026, with net sales growth of 17-20% at constant currency and a Core EBITDA margin of approximately 26% at constant currency. Based on the strong start to the year, the guidance is increasingly being de-risked with confidence to navigate a volatile environment.

 

 

On U.S. tariffs, exposure is expected to remain manageable in the year. In addition to the already assumed 15% U.S. tariff on the import values of Sculptra and Restylane, the confirmed full year guidance now also factors in the expected effects of the recent U.S. administration proclamation on the imports of pharmaceuticals and pharmaceutical ingredients into the U.S.

 

 

The evolution from February to March of the simulated foreign exchange impact is available in the Appendix, highlighting key foreign exchange currency pairs.

 

 

2026 remains a key year to capitalize on opportunities and drive net sales growth. The five key opportunity areas for the year include 1) significant launches, including the strong uptake of Nemluvio and Relfydess, the geographic expansion of Restylane and Sculptra, and ongoing innovation in Dermatological Skincare, 2) further market share gains, 3) a strengthened financial profile, 4) a shift to long-term growth with increasing strategic optionality, and 5) dynamic commercial investments to continue to drive growth.

 

 

Webcast details

 

 

Galderma will host a trading update call today at 15:30 CEST to discuss first quarter 2026 results and respond to questions from financial analysts. Investors and the public may access the webcast by registering on the Galderma Investor Relations website at https://investors.galderma.com/events-presentations. A recording will also be made available after the event.

 

 

About Galderma

 

 

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

 

 

Appendix

 

 

Appendix 1: Q1 2026 net sales by product category and geography

 

 

In million USD		Net sales			Year-on-year growth
		Q1 2025	Q1 2026		Constant currency	Reported
Group total		1,129	1,473		25.5%	30.5%
By product category
Injectable Aesthetics		547	648		13.1%	18.4%
Neuromodulators		311	364		12.5%	17.1%
Fillers & Biostimulators		236	284		14.0%	20.1%
Dermatological Skincare		370	441		17.0%	19.3%
Therapeutic Dermatology		212	385		71.3%	81.4%
of which Nemluvio		39	185		>100%	>100%
By geography
International		697	862		16.0%	23.7%
U.S.		432	610		41.5%	41.5%

 

Appendix 2: Overview of foreign exchange rate exposure

 

FX rates compared to USD		FY 2025 average rate		February 2026 closing rate (recall)		March 2026 closing rate
AUD		0.645		0.713		0.685
BRL		0.179		0.195		0.190
CHF		1.206		1.294		1.252
CNY		0.139		0.146		0.145
EUR		1.130		1.181		1.147
MXN		0.052		0.058		0.055
Simulation of FX impact for 2026 full-year absolute figures3
		Net sales		+245 bps		+105 bps
		Core EBITDA		+144 bps		+45 bps

 

Notes and references

 

Note: Due to rounding numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. All ratios, subtotals and variances are calculated using the underlying amount rather than the presented rounded amount.

 

 

1. Constant currency year-on-year growth is defined as the annual growth rate of net sales excluding the impact of exchange rates movements and excluding hyperinflation economies as and when applicable. The impact of changes in foreign exchange rates are excluded by translating all reported revenues during the two periods at average exchange rates in effect during the previous year.
2. Dividend-bearing shares are all shares issued except for treasury shares held by Galderma Group AG or its direct or indirect fully owned subsidiaries as of the record date. The dividend of 0.35 CHF per share will be paid in CHF. The payment will be made as of April 28, 2026 to holders of shares on the record date April 27, 2026. The shares will be traded ex-dividend as of April 24, 2026 and, accordingly, the last day on which the shares may be traded with entitlement to receive the dividend will be April 23, 2026.
3. Factors in the simulation of all foreign exchange rate exposures, including for currencies not listed in the table of exchange rates for top FX exposures

 

Forward-looking statements
Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “plans”, “targets”, “aims”, ” believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “continues”, “should” and similar expressions. These forward-looking statements reflect, at the time, Galderma’s beliefs, intentions and current targets/ aims concerning, among other things, Galderma’s results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management’s current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260422930888/en/

 

Business Wire India

The Chatterjee Group (TCG), a multi-billion-dollar global conglomerate, announced a major acceleration of its strategic expansion into high-growth, digital-first consumer markets. This new phase was marked by the successful launch of a direct-to-consumer (D2C) platform for its iconic brand, Garden Vareli, unveiled by TCG Chairman Dr. Purnendu Chatterjee at a marquee event in Mumbai recently.

This strategic pivot signifies TCG’s deliberate foray from its core industrial and petrochemical base into the dynamic B2C retail landscape. The move is a calculated step in the group’s long-term vision to build and scale digitally-native enterprises, applying its formidable financial strength and operational expertise to capture new consumer segments. This expansion reflects TCG’s core philosophy of investing in and transforming knowledge-intensive businesses for future growth.

TCG’s formidable legacy is built on creating and mastering entire value chains. A leader in the chemicals and petrochemicals sectors, TCG is the parent of industry giants like Haldia Petrochemicals Ltd. (HPL) and MCPI Pvt. Ltd. The group’s strategic might was further demonstrated with the acquisition of Lummus Technology, a global leader in process technologies. Beyond its industrial core, TCG’s diverse portfolio fosters innovation through entities including TCG Life Sciences, TCG Digital, and TCG Real Estate, all underpinned by a relentless pursuit of knowledge through the Centre for Research and Education in Science and Technology (TCG CREST).

“TCG has always been driven by a passion for transformation and building enduring value. Garden Vareli holds a special place in the legacy of Indian households, and our vision is to reinvigorate this connection for a new era,” stated Dr. Purnendu Chatterjee, Founder and Chairman, TCG. “This digital launch is a pivotal moment, representing our commitment to not only preserving a legacy but evolving it through direct, meaningful engagement with the consumer. It is a blueprint for how TCG will build the next generation of consumer-centric businesses.”

The Garden Vareli D2C launch is the first major public initiative in this new chapter, serving as a powerful proof point of TCG’s strategy in action. By transforming a brand with a rich legacy as a staple in Indian homes into an agile, AI-enabled digital entity, TCG is showcasing its capability to unlock value and drive innovation. This launch is the cornerstone of a broader strategy to establish the brand as an omnichannel powerhouse, integrating a robust wholesale and retail network with a comprehensive presence on online marketplaces. The new platform is envisioned not just as a sales channel, but as a scalable digital marketplace and a future ‘House of Brands,’ supporting an ambitious expansion into Salwar Kameez Dupattas (SKDs) and fusion wear, demonstrating TCG’s ambition to become a significant player in India’s digital economy.

Adding to this, Mr. Debi Prasad Patra, Managing Director & CEO – MCPI Private Limited and Director – Garden Silk Fashions Private Limited, commented, “For decades, Garden Vareli has been a part of the fabric of Indian life. Our revitalized omnichannel strategy ensures we connect with our customers wherever they are: online, in marketplaces, or in stores. With our new D2C platform as the digital flagship, we are not just re-establishing our leadership in sarees but also expanding into SKDs and fusion wear, creating a complete wardrobe solution for the modern woman.“

“As we usher Garden Vareli into its digital-first era, our focus is on creating a seamless omnichannel experience,” added Dr. Mahendra Singh Bhadouria, CEO of Garden Vareli. “This D2C platform is our digital front door, showcasing our technological prowess and allowing us to connect directly with our community. The insights gained here will help us innovate across our entire product range, from our iconic sarees to our new fusion wear, ensuring we deliver a unique blend of tradition and contemporary design that truly resonates.“

This commitment to shaping the future was vibrantly showcased at the star-studded launch event in Mumbai. Themed ‘One Garden, Many Seasons,’ the evening celebrated the brand’s evolution with a stunning showcase of its new and contemporary designs. The grand finale culminated with celebrated Bollywood star Bhumi Satish Pednekkar as the showstopper, embodying the confident, modern spirit of the new Garden Vareli and marking a glamorous beginning to TCG’s new consumer-focused era. To know more, visit www.gardenvareli.com

Business Wire India

Material, an intelligent growth company providing consumer data and insights, brand strategy and product innovation, is pleased to welcome Raman Kalra as President, Asia Pacific (APAC).

 

Kalra’s appointment comes as Material continues to expand its global footprint with capabilities across insights, strategy, design and marketing technology. Kalra will lead the company’s APAC operations, bringing AI-driven data- and technology-enabled solutions closer to both global and local clients for whom the region is strategically vital.

 

 

Laila Worrell, Material’s CEO, stated, “This is a transformative time for the industry and our clients. Raman’s expertise in AI-driven transformation and success in APAC makes him the ideal leader as we deepen our commitment to clients who compete in and across this vibrant, growing market.”

 

 

Specializing in business transformation and demand engineering through data-backed insights, Kalra will partner with global teams to deliver Material’s full strategy-to-execution capabilities of insights, design and marketing technology to clients across the region.

 

 

Kalra commented, “I am excited to lead Material in APAC as we intensify our commitment to global clients and especially the region. This is a pivotal moment for the industry as we reimagine how human insights and AI-first technology redefine how brands grow and businesses perform. I look forward to leveraging the company’s deep legacy of behavioral insights to build tech-based solutions that help our clients not only understand their markets but also shape them.”

 

 

About Raman Kalra, President, Asia Pacific

 

 

Raman Kalra brings over 30 years of experience at the intersection of strategy, technology and enterprise growth. He previously served as a senior partner with IBM and PwC Consulting, where he led AI-first growth strategies for global brands across media, telecom and energy.

 

 

Most recently, he led Business Transformation Services for IBM in India and South Asia, managing an end-to-end portfolio across digital strategy, AI transformation and customer experience (CX). He also engineered the cross-border acquisition of a Belgian digital energy venture for ReNew, successfully diversifying their portfolio.

 

 

About Material

 

 

Material is an intelligent growth company. Fueled by a powerful core in market research, behavioral science and data analytics, Material has a 50-year history of building customer intelligence into brands and experiences that compete and win. Material works with world-class companies to anticipate and capitalize on cultural and market shifts, understand and influence consumer behavior and shape demand. Integrated capabilities across insights-driven strategy, design innovation and customer engagement bring clients clear growth choices and solutions that drive outsized business impact. In addition to serving the corporate market, Material has helped some of the world’s most celebrated cultural icons extend their personal brands into new product lines. Learn more at materialplus.io.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260422271493/en/

 

Business Wire India

I/ONX High Performance Compute (HPC), a leading provider of heterogeneous AI systems, today announced the global launch of the Symphony SixtyFour, a high-density platform designed to collapse the physical and economic footprint of AI inference and fine-tuning infrastructure. By supporting up to 64 accelerators on a single node, I/ONX eliminates the redundant Host Tax—the massive overhead in power, hardware, and licensing that negatively impacts ROI in enterprise AI.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422485327/en/

 

 

 

While inference now accounts for 90% of enterprise AI workloads, enterprises are entirely limited to deploying inference on training hardware platforms. Symphony SixtyFour provides significant advantages for reduced CapEx and OpEx for inference and fine-tuning workloads. In training comparisons, the I/ONX system recovers the 30kW Host Tax typically wasted on redundant CPUs, memory, and support hardware in multi-node clusters and simplifies ongoing support tasks. For production-scale inference on alternative accelerators, the platform is even more transformative, drawing one-fourth the power of a traditional 64-device cluster—completely eliminating liquid cooling needs for inference only.

 

“Enterprise AI infrastructure is entering a new phase of maturity,” said I/ONX CEO Justyn Hornor. “The training-centric designs of the past served us well during the experimental phase, but they weren’t optimized for the power-constrained, production-heavy world we live in today. With Symphony SixtyFour, we’ve reimagined the stack to be more fluid and fit for purpose, allowing organizations to master massive-scale inference while finally eliminating the unnecessary infrastructure waste that has hindered ROI.”

 

 

The Symphony SixtyFour Advantage: Fit for purpose Silicon. The platform is engineered to maximize every watt and dollar for Enterprise AI.

 

 

• Eliminating the Training Host Tax: For large-scale inference and fine-tuning, Symphony SixtyFour collapses the infrastructure stack from eight nodes into one. This consolidation removes up to 30kW of wasted support power, allowing for higher compute density within existing power envelopes.
• Zero-Hop, near-Deterministic Performance: By housing 64 accelerators within a single OS instance, Symphony SixtyFour eliminates the East-West network latency.
• Heterogeneous Flexibility: Symphony SixtyFour is fully vendor-neutral and built for mixed-mode operations. Enterprises can seamlessly pair high-end GPUs (including AMD/NVIDIA) with more purpose built, low power co-processors and layer in specialized inference silicon (Axelera/FuriosaAI/Tenstorrent) future-proofing infrastructure against shifting market dynamics.
• Collapsing OpEx by simplifying the Host Tax: Beyond hardware and power, Symphony SixtyFour provides massive operational relief. By presenting a 64-device fleet through a single management environment, I/ONX collapses the Software Tax, saving enterprises up to $500,000 annually in Enterprise Operating Systems and orchestration licensing per cluster.

 

I/ONX accelerates the enterprise shift toward systems designed specifically for inference and fine-tuning at scale. Symphony SixtyFour is available now, enabling organizations to reclaim critical power capacity and reduce costs. I/ONX is committed to delivering high-density infrastructure required to unlock the maximum economic and operational potential of production AI.

 

About I/ONX

 

 

I/ONX High Performance Compute (HPC) is the pioneer of heterogeneous AI infrastructure, and is redefining the AI lifecycle by eliminating the Host Tax of legacy architectures. The I/ONX flagship Symphony SixtyFour consolidates up to 64 accelerators into a single node, reducing rack-scale TCO by 50% or more. By dramatically lowering power consumption and maximizing hardware utilization, I/ONX enables enterprises to achieve production-scale AI with unprecedented efficiency and faster ROI.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260422485327/en/